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Does cisplatin-based chemotherapy reduce the risk of a metachronous contralateral 
(second) testicular cancer? 
 
The overall 20-year cumulative incidence of second testicular cancer in a population-
based cohort was 4%. Treatment with cisplatin-based chemotherapy significantly 
reduced the second testicular cancer risk, with a stronger risk reduction for each 
additional cisplatin-based chemotherapy cycle administered. Older age at diagnosis 
of first testicular cancer also reduced the risk.  
 
Our findings add important knowledge concerning the risk of second testicular 
cancer. Our results are important and appreciated information for testicular cancer 







It is hypothesized that cisplatin-based chemotherapy (CBCT) reduces the occurrence 
of metachronous contralateral (second) germ cell testicular cancer (TC). However, 
studies including treatment details are lacking. The aim of this study was to assess 
the second TC risk, emphasizing the impact of previous TC treatment. 
 
Methods 
Based on the Cancer Registry of Norway, 5620 men were diagnosed with first TC 
between 1980-2009. Treatment data regarding TC were retrieved from medical 
records. Cumulative incidences of second TC were estimated, and standardized 
incidence ratios (SIRs) were calculated. The effect of treatment intensity was 
investigated using Cox proportional hazard regression.  
 
Results 
Median follow-up was 18.0 years, during which 218 men were diagnosed with a 
second TC, after median 6.2 years. Overall, the 20-year crude cumulative incidence 
was 4.0% (95% CI 3.5-4.6), with lower incidence after chemotherapy (3.2%, 95% CI 
2.5-4.0) than after surgery only (5.4%, 95% CI 4.2-6.8). The second TC incidence 
was also lower for those aged 30 years (2.8%, 95% CI 2.3-3.4) at first TC diagnosis 
than those <30 years (6.0%, 95% CI 5.0-7.1). Overall, the second TC risk was 13-
fold higher compared with the risk of developing TC in the general male population 
(SIR 13.1, 95% CI 11.5-15.0). With surgery only as reference, treatment with 
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chemotherapy significantly reduced the second TC risk (HR 0.55). For each 
additional CBCT cycle administered, the second TC risk decreased significantly after 
3, 4 and >4 cycles (HRs 0.53, 0.41, and 0.21 respectively).  
 
Conclusion 
Age at first TC diagnosis, as well as treatment intensity, influenced the second TC 






After being diagnosed with a primary germ cell testicular cancer (TC), the estimated 
15 to 20-year cumulative incidence of a metachronous contralateral (second) TC is 
1.9-3.9%.1-4 Standardized incidence ratios (SIRs), comparing the incidence of second 
TC to the incidence of TC in the general population, range from 12.4 to 35.7.1-7 
Treatment of the second TC will usually involve a surgical castration, leading to 
infertility and life-long dependency of testosterone substitution.8,9 From personal 
experience, many testicular cancer survivors (TCS) with unilateral disease fear losing 
their remaining testicle.  
Shared etiological factors for the first and second TC, hypothesized to cause 
the testicular dysgenesis syndrome, represent a likely explanation for the increased 
incidence of a second TC.10,11 Young age at diagnosis of the first TC is associated 
with increased risk of developing a second TC.1-4,12 Results are, however, 
inconclusive regarding the effect of first TC histology and subsequent second TC 
risk.1,4,7,13,14 
The introduction of cisplatin in the late 1970s led to a dramatically improved 
survival of patients with metastatic TC.15,16 Cisplatin-based chemotherapy (CBCT) is 
hypothesized to reduce or delay the incidence of a metachronous contralateral TC. 
However, the existing literature either lacks TC treatment details if based on public 
registries,1,2 involves populations screened for germ cell neoplasia in situ 
(GCNIS),12,17 or includes patients treated in the pre-cisplatin era.3-5  
 Andreassen et al investigated the risk for metachronous contralateral TC in 
7102 TCS in Norway, treated during 1953-2007.2 They found a 50% risk reduction for 
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a second TC in men treated for metastatic compared to localized disease only for 
those treated after 1980, implying that this risk reduction was related to the 
introduction of CBCT. They emphasized that the greatest limitation of their study was 
the lack of TC treatment details. Furthermore, Fosså et al conducted a large register-
based study involving 29151 TCS from the US. They concluded that “a potential 
dose-response relationship between cisplatin and eradication of germ cell carcinoma 
in situ should be investigated in future clinical studies”.1  
The aim of this population-based study was to assess the risk of developing a 
metachronous contralateral TC, with emphasis on the impact of previous TC 
treatment including CBCT, in a national cohort with complete data on TC treatment. 
 
Patients and Methods 
Study Cohort and Design 
The Cancer Registry of Norway (CRN) identified men diagnosed with histologically 
verified primary germ cell TC from January 1, 1980 to December 31, 2009.18 Major 
exclusion criteria included age <16 years at TC diagnosis, a prior malignancy, 
extragonadal germ cell cancer, and synchronous contralateral TC or death within 2 
months of follow-up (Supplemental Appendix, Fig S1). Metachronous TC was defined 
as a second germ cell TC diagnosed >2 months after the primary TC.  
 After exclusions, this historical prospective cohort study consisted of 5620 TC 
patients. Details regarding disease stage, histology and TC treatment for first and 
second TC, including relapse treatment, were retrieved from medical records. 
Linkage with the CRN updated through December 31, 2018 was done to ensure 
complete information on incidence of second TC. 
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The study was approved by the Regional Committee for Medical and Health 
Research Ethics and the Data Protection Authorities at the University Hospital of 
North Norway. Passive consent from all eligible men still alive was obtained through 
a study information letter with the possibility to withdraw from participation, after 
which 23 (0.38%) men declined participation. 
  
Staging, Treatment and Treatment Groups 
TC was staged according to the Royal Marsden Hospital staging system.19 During 
the study period, the treatment principles for TC changed as previously described.20 
Adjuvant radiotherapy (RT) for stage I seminoma has gradually been abandoned, 
and the number of CBCT cycles applied for metastatic disease has been reduced. 
The use of a risk-adapted surveillance strategy or 1 cycle of adjuvant CBCT 
(nonseminoma) or carboplatin (seminoma) for stage I disease has been implemented 
as recommended by the Swedish and Norwegian Testicular Cancer Group 
(SWENOTECA).21 
 Based on total treatment burden for the first TC, the cohort was divided into 
four treatment groups: Surgery only (including surveillance n=1417; 25%), 
chemotherapy (CT, n=2450; 44%), RT (n=1543, 27%), and both CT and RT (CT+RT, 
n=210; 3.7%) (Table 1).  
   
Statistical Methods 
Continuous variables were presented with median and interquartile range (IQR), and 
categorical variables were presented with numbers and percent. 
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 Follow-up was calculated from 2 months after diagnosis of the first TC until a 
diagnosis of a second TC, death, emigration or December 31, 2018, whichever 
occurred first. Treatment was analysed as a time-varying covariate, achieved by 
splitting follow-up time at exact treatment dates for each treatment modality, to avoid 
immortal time bias. The K-sample median test was used to test differences in median 
time to second TC among those developing a second TC, presented with two-sided 
p-values. 
 The crude cumulative incidence of metachronous contralateral TC was 
estimated using the Aalen-Johansen estimator,22 with death of any cause as a 
competing risk. To compare the incidence of metachronous contralateral TC to the 
incidence of TC in the general population, SIRs were calculated. The estimates were 
obtained by dividing the number of metachronous contralateral TCs in the cohort to 
the expected number of metachronous contralateral TC, given the incidence of TC in 
a comparable Norwegian male population, matched by 5-year age groups and 
calendar year of follow-up. Cumulative incidences and SIRs with respective 95% 
confidence intervals (CIs) were calculated for the whole cohort, and stratified 
according to treatment groups, age at diagnosis, follow-up time and histology.  
The effect of treatment and histology on the second TC risk were evaluated 
using Cox proportional hazard regression models with time since diagnosis as time 
scale, the surgery only group as reference and adjusting for age at diagnosis.20 
Additionally, histology as risk factor was investigated in a multivariable Cox 
regression model which included treatment. Cumulative chemotherapy doses were 
estimated based on CT regimen and number of CT cycles. The Cox regression 
model was also used to evaluate the effect of age at diagnosis (dichotomized). A 
nonsignificant Schoenfeld test showed that the proportional hazard assumption was 
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met for all analyses except for cumulative doses (Supplemental Appendix Table S1) 
and the dichotomized age variable (p=0.049). For the latter, the proportional hazard 
assumption was judged to be met by visual inspection of a -log-log survival plot. The 
results are presented as hazard ratios (HRs) with corresponding 95% CIs and p-
values.  
Data were analysed using Stata statistical software (version MP 16.1; STATA, 
College Station, TX). A p-value <0.05 was considered significant.  
 
Results 
Characteristics of the Total Study Cohort and the Metachronous TC Sub-Cohort 
The total study cohort consisted of 5620 men with a median follow-up time of 18 
years (IQR 12.0-25.5) (Table 1). Median age at diagnosis was 33 years, 38% were 
<30 years, and 70% were diagnosed with stage I disease at first TC. Overall, 25% 
were treated with surgery only and 44% were treated with CT at first TC. 
Overall, 218 (3.9%) men developed a metachronous contralateral TC after 
median 6.2 years (IQR 3.3-10.6) (Table 1). Among these 218 men, median age at 
first TC diagnosis was 28.7 years, 57% were <30 years at diagnosis of first TC, and 
seminoma (49%) and nonseminoma (51%) histology of the first TC was equally 
distributed. Furthermore, 80% were diagnosed with clinical stage I at first TC, and as 
treatment for first TC 33% had surgery only and 32% received CT. Median time to 
second TC did not differ according to treatment (p=0.55), or age at diagnosis of first 
TC (p=0.10) (Supplemental Appendix, Table S2). 
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The majority of the second TCs were seminomas (72%) (Supplemental 
Appendix, Table S3). At diagnosis of the second TC, 84% had stage I disease, and 
53% were treated with surgery only.  
 
Cumulative Incidences of Second TC 
The overall crude cumulative second TC incidence was 4.0% (95% CI 3.5-4.6) at 20 
years (Fig 1A, Table 2). The second TC incidence was lower in those aged ≥30 years 
at first TC diagnosis (2.8%, 95% CI 2.3-3.4) than in those <30 years (6.0%, 95% CI 
5.0-7.1) (Fig 1B). The second TC incidence was also lower after treatment with CT 
(3.2%, 95% CI 2.5-4.0) and CT+RT at first TC (1.4%, 95% CI 0.4-3.9), than after 
surgery only (5.4%, 95% CI 4.2-6.8) or RT (4.5%, 95% CI 3.6-5.6) (Fig 1C).  
For those aged <30 years at first TC diagnosis, 20-year cumulative incidence 
after surgery only was 8.0% (95% CI 5.8-10.6) and after CT it was 4.8% (95% CI 3.6-
6.3) (Table 2). In comparison, for those aged ≥30 years at first TC diagnosis, the 
second TC incidence was 3.2% (95% 2.1-4.6) after surgery only and 1.7% (95% CI 
1.1-2.7) after CT.  
The second TC incidence did not differ according to first TC histology, with 
estimates of 3.8% (95% CI 3.1-4.6) after seminoma and 4.3% (95% CI 3.5-5.1) after 
nonseminoma (Fig 1D).  
 
Risk of Second TC in Relation to the General Population  
Overall, the second TC risk was 13-fold higher compared with the risk of developing 
TC in the general population (SIR 13.1, 95% CI 11.5-15.0) (Table 3). The risk was 
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lower after treatment with CT (SIR 9.1, 95% CI 7.2-11.5) and CT+RT (SIR 8.6, 95% 
CI 2.8-26.7) at first TC than after surgery only (SIR 16.3, 95% CI 12.9-20.5) and RT 
(SIR 17.7, 95% CI 14.1-22.3). SIRs decreased with increasing age at diagnosis, and 
was highest for those aged 20-30 years (SIR 14.0, 95% CI 11.7-16.8.). The risk for a 
second TC was highest within the first 5 years of follow-up after diagnosis of the first 
TC (SIR 17.0, 95% CI 13.7-21.2), and decreased with increasing follow-up time. 
 
Hazard Ratios for Second TC 
With surgery only as the reference group, the second TC risk was significantly lower 
after treatment with CT at first TC (HR 0.55, 95% CI 0.40-0.76) (Table 4). A 
sensitivity analysis excluding those treated with CT other than CBCT (carboplatin-
based, n=332; other CT, n=2) was performed with no significant change of results 
(data not shown). Treatment with RT did not affect the second TC risk (HR 1.10, 95% 
CI 0.79-1.54).  
For each additional CBCT cycle administered, the point estimates for second 
TC risk decreased, with significantly reduced risks after 3 (HR 0.53, 95% CI 0.29-
0.97), 4 (HR 0.41, 95% CI 0.25-0.66), and >4 cycles (HR 0.21, 95% CI 0.07-0.66) 
(Table 4, Fig 2). The hazard of second TC was not significantly different after 
treatment with adjuvant carboplatin monotherapy (HR 1.22, 95% CI 0.62-2.39). For 
each increase of 100 mg/m2 cisplatin, the second TC risk decreased equivalent to the 
results according to number of CBCT cycles. The effect on second TC risk was 
weakened for the dose level 101-200 mg/m2 when carboplatin was included in the 
analysis of cumulative platinum doses (Supplemental Appendix, Table S1). 
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 The second TC risk was significantly reduced for those ≥30 years at first TC 
diagnosis (HR 0.47, 95% CI 0.36-0.62). In age-adjusted Cox regression, 
nonseminoma histology at first TC was associated with decreased risk of second TC 
(HR 0.73, 95% CI 0.55-0.98). However, compared to seminoma, this association 
disappeared when treatment at first TC was included in the model (HR 0.97, 95% CI 
0.65-1.45) (Table 4).   
 
Discussion 
In this population-based study, the overall 20-year cumulative incidence of a 
metachronous TC was 4.0% in a well described cohort with complete information on 
total treatment burden and long follow-up time. We demonstrated, to the best of our 
knowledge for the first time, that the risk of a metachronous contralateral TC 
decreased with each additional CBCT cycle administered, with significantly reduced 
risks after >2 CBCT cycles.  
The overall second TC cumulative incidence of 4% and total SIR of 13.1 found 
in this study is in accordance with existing literature.1-7 We found a reduced second 
TC risk after treatment with CT at first TC, and our results lend strong support to the 
hypothesis that cisplatin reduces the second TC risk.1-3,5 Treatment with RT has not 
been considered to affect the TC incidence,3,4,12 and our results are in agreement 
with this. Adjuvant infradiaphragmatic RT after seminoma results in a total dose of 
0.09-0.32 Gy of scattered radiation to the remaining testicle, which is probably 
insufficient for eradication of GCNIS if present.23    
GCNIS is the precursor of germ cell TC.24 If left untreated for 5 years, 50% of 
patients with GCNIS will develop an invasive cancer.25 There has not been a tradition 
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to screen for GCNIS in Norway during the study period, as it has only been 
performed in selected high-risk patients.17,26,27 Metastatic TC is highly sensitive to 
cisplatin. However, cisplatin seems to have a modest but possibly dose-dependent 
effect on eradication of GCNIS.17,25,28-31 In the present study, we found a strong 
association between the number of CBCT cycles, as well as cumulative cisplatin 
dose, and the second TC risk. Our results are in line with the study by Brabrand et al, 
who found significantly reduced second TC risk after ≥4 compared to 1-3 CBCT 
cycles or no CT in a study of 61 TCS with biopsy-proven GCNIS in the contralateral 
testicle.17 We found no risk reduction after 1-2 CBCT cycles, which corroborates 
results from a prospective study on second TC risk after 1-2 adjuvant CBCT cycles in 
patients with stage I nonseminoma.26 In contrast to the results from the randomized 
trial by Oliver et al comparing adjuvant carboplatin with RT,32 we found no decrease 
of second TC risk after treatment with adjuvant carboplatin.  
The modulating effect of the blood-testis barrier on the intratubular 
concentration of cytotoxic drugs,33,34 possibly in part explain the need for higher 
cumulative doses of cisplatin before effect on GCNIS and the subsequent second TC 
risk. However, cisplatin undoubtedly has an effect in the testis, demonstrated by the 
decrease of sperm concentration and quality and the changes of sperm DNA 
following CBCT.35-37 Furthermore, there seems to be a relationship between number 
of CBCT cycles and the recovery of spermatogenesis.36-39 A recent publication by 
Weibring et al did not find long-term reduction of sperm count after 1 cycle of 
CBCT.40 On the other hand, three or more cycles of CBCT may lead to long-term or 
permanent impairment of sperm function.36-38  
It has been suggested that cisplatin delays, rather than reduces, the 
development of a second TC.29,31 In accordance with Schaapveld et al,3 our results 
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do not lend support to this hypothesis. On the contrary, we found that there was a 
longer median time interval between first and second TC after surgery only (7.0 
years) than after CT (5.8 years), although not statistically significant. The overall 
latency of 6.2 years between first and second TC agrees with previous studies.1-3 In 
the present study, with a very long follow-up time of median 18 years, 72% of second 
TCs developed within 10 years of follow-up. This is in line with the report of a plateau 
in incidence after 15-20 years.3,4 However, second TCs may occur late,41 and the 
longest time interval between first and second TC in our cohort was 27 years.  
A polygenic susceptibility, coupled with fetal and early-life environmental 
factors, are involved in TC development.10,11,42-45 The shared prenatal predisposition 
of the first and second TC probably accounts for the increased risk of metachronous 
contralateral TC, and the increased risk in younger vs. older men is in turn 
presumably explained by this.1,46 Young age at TC diagnosis has been established 
as an important risk factor for developing metachronous contralateral TC, 1-4,12,13,47 
and our results are in complete agreement with this. In our study, median age at 
diagnosis of first TC was 4.6 years younger in men who later developed a second TC 
than men with unilateral TC. Furthermore, men aged <30 years at first TC had more 
than twice as high 20-year cumulative second TC incidence than those 30 years or 
older at first TC diagnosis.  
The current knowledge regarding histology and the risk of metachronous 
contralateral TC are inconsistent.1,4,7,13,14 Studies conducted in the pre-cisplatin era 
found a higher risk for metachronous contralateral TC after nonseminoma than after 
seminoma.4,14  In the cisplatin era, some studies concluded with the opposite,7,13 
supporting an effect of CBCT.1 We found no association between first TC histology 
and the risk of a second TC when adjusting for age and treatment, which is in line 
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with Andreassen et al.2 Our results suggest that the differences found in 
histology,1,4,7,13,14 are in fact caused by the effect of CBCT, as patients with 
nonseminoma more often are treated with CBCT than patients with seminoma. 
In a recent review by Zequi et al, 60.4% of metachronous contralateral TCs 
had a seminoma histology.48 This is in line with the present study where 72% of the 
second TCs were seminomas. The abundancy of seminoma histology of second TCs 
are probably caused by age.18  
 In our study, the majority (84%) of second TCs were diagnosed as clinical 
stage I, and this correlates to the results published in the review by Zequi et al 
(73.3% in stage I).48 Our even higher proportion diagnosed in stage I might be a 
result of robust follow-up procedures, centralized treatment of TC in Norway, and of 
the risk-adapted biopsy-strategy of the contralateral testicle.27,49  
 Important strengths of our study include the consideration of a nation-wide 
cohort, the completeness of cancer incidence rates of the CRN,18 and the complete 
information on treatment burden in a large and unselected study cohort with long 
follow-up time. The risk-adapted treatment strategy in clinical stage I disease 
recommended by SWENOTECA, has made it possible to compare adjuvant CT with 
the surveillance strategy.21  
The lack of information regarding GCNIS and risk factors for TC, such as 
family history of TC, history of cryptorchidism or infertility, are potential limitations. 
Tissue samples available for genetic analyses could have been of particular interest. 
In conclusion, we found a strong association between number of CBCT cycles 
and the subsequent risk of a metachronous contralateral TC. Patients with metastatic 
unilateral TC might appreciate information on the significant risk-reduction of second 
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TC after treatment with CT. Even though most second TCs develop within 10 years 
after diagnosis of the first TC, they may develop after more than 20 years. It is 
important that TCS are aware of this risk and that the importance of regular life-long 
self-examination is emphasized. 
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Crude cumulative incidences of metachronous contralateral testicular cancer by 
follow-up time. A) All patients (with 95% confidence interval), B) by age at first TC, 
dichotomized C) by treatment groups at first TC, and D) by histology at first TC. In A, 
the red line indicates the incidence of metachronous contralateral TC, and the blue 
area indicates the 95% confidence interval. 
Abbreviations: TC; testicular cancer; CT; chemotherapy, RT, radiotherapy, CT + RT, 
combination of CT and RT 
 
Figure 2 
Proportion diagnosed with metachronous contralateral testicular cancer by follow-up 
time and number of cisplatin-based chemotherapy cycles, adjusted for age at 
testicular cancer diagnosis. The risk table presents crude number of individuals by 
follow-up time. 
Abbreviations: TC, testicular cancer  
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Figure 1.  
 


























Table 1. Patient characteristics at first primary TC diagnosis 
 
 Total at risk  
(n = 5620) 
Individuals without 
second TC  




Decade of first TC diagnosis    
1980-1989 1287   (23) 1228   (23)   59   (27) 
1990-1999 1897   (34) 1824   (34)   73   (34) 
2000-2009 2436   (43) 2350   (43)   86   (39) 
Follow-up, y, median (IQR)*  18.0 (12.0-25.5) 18.5 (12.5-25.8)   6.2 (3.3-10.6)† 
Age at diagnosis, y, median (IQR) 33.0 (27.2-40.9) 33.3 (27.3-41.2) 28.7 (24.6-33.5) 
Age at diagnosis, dichotomized    
<30 years 2124   (38) 1999   (37) 125   (57) 
≥30 years 3496   (62) 3403   (63)   93   (43) 
Histology    
Seminoma 2938   (52) 2831   (52) 107   (49) 
Nonseminoma 2682   (48) 2571   (48) 111   (51) 
Initial disease stage‡    
I 3942   (70) 3766   (70) 176   (80) 
Mk+/II 1127   (20) 1097   (20)   30   (14) 
III   116   (2.1)   114   (2.1)     2   (1.0) 
IV   435   (7.7)   425   (7.9)   10   (4.6) 
Treatment§     
Surgery only** 1417   (25) 1345†† (25)   72   (33) 
CT 2450   (44) 2379   (44)   71   (32) 
RT 1543   (27) 1471   (27)   72   (33) 
CT + RT   210   (3.7)   207   (3.8)     3   (1.4) 
Cause of first-line CT    
Adjuvant, CS I   843   (32)   811   (31)   32   (43) 
Primary metastatic disease 1538   (58) 1502   (58)   36   (49) 
Recurrence   279   (10)   273   (11)     6   (8.1) 
First CT regimen    
BEP-20 1507   (57) 1464   (57)   43   (58) 
CVB   367   (14)   357   (14)   10   (13.5)  
EP   241   (9.1)   237   (9.2)     4   (5.4) 
Other CBCT‡‡   184   (6.9)   180   (6.9)     4   (5.4) 
Adjuvant Carboplatin§§   295   (11)   285   (11)   10   (13.5)  
CEB     44   (1.6)     42   (1.6)     2   (2.7) 
Other***      22   (0.8)     21   (0.8)     1   (1.4) 
No. of CBCT cycles†††    
1   220   (9.5)   210   (9.3)   10   (16)    
2   319   (14)   307   (14)   12   (20) 
3   439   (19)   427   (19)   12   (20) 
4 1028   (44) 1004   (44)   24   (39)  
> 4   320   (14)   317   (14)     3   (4.9) 
RT first field    
L-field‡‡‡ 1388   (79) 1321   (79)   67   (89) 
Paraaortal   267   (15)   260   (15)      7   (9.3) 
Supradiafragmatic     13   (0.7)     12   (0.7)     1   (1.3) 
Supra- and infradiafragmatic§§§     21   (1.2)     21   (1.3)     0 
Other****     64   (3.6)     64   (3.8)     0 
RT dose for first RT field    
1-20 Gy     13   (0.7)     12   (0.7)     1   (1.3) 
20-29Gy   514   (29)   490   (29)   24   (32) 
30-39 Gy   986   (56)   943   (56)   43   (57) 
≥40 Gy   240   (14)   233   (14)     7   (9.3) 
Note: Data are presented as n (%), unless otherwise stated.  
Abbreviations: TC, testicular cancer; n, number; y, years; IQR, interquartile range; Mk+, marker positive; CT, 
chemotherapy; RT, radiotherapy; CT + RT, combination of CT and RT; CS I, clinical stage I; BEP-20, bleomycin, 
etoposide and cisplatin; CVB, cisplatin, vinblastine and bleomycin; EP, etoposide and cisplatin; CBCT, cisplatin-
based CT; CEB, carboplatin, etoposide and bleomycin; no, number; Gy, grey,
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* Follow-up until diagnosis of metachronous contralateral TC, death, emigration or December 31st 2018, 
whichever occurred first.  
† The longest time interval between first and second TC was 27.1 years.  
‡ As described by Peckham et al.19  
§ Based on total treatment burden. 
** The surgery only group included men followed with surveillance after orchiectomy (n = 1167; 21%) and men 
who underwent additional retroperitoneal lymph node dissection without CT or RT (n = 250; 4.4%). 
†† Two men included in the surgery only group were diagnosed with clinical stage IV. One refused treatment and 
the other was no candidate for treatment. They both died shortly (but >2 months) after diagnosis. 
‡‡ Of which a total of 141 were dose-escalated CBCT.  
§§ 15 of the 295 men initially treated with adjuvant carboplatin were subsequently treated with CBCT, and as a 
consequence analysed according to total number of cisplatin-based chemotherapy cycles. Also, 1 person had RT 
in addition to carboplatin. Of the 279 men treated with adjuvant carboplatin monotherapy included in the Cox 
regression analysis, 273 received 1 cycle and 6 received 2 cycles. 
*** Carboplatin monotherapy in metastatic setting (n=17), sendoxan/adriamycin (n=1), CAOS (actinomycin D, 
adriamycin, vincristine, sendoxan) (n=3), actinomycin D (n=1). 
††† May have received additional CT regimes, but these are not accounted for in this number. A total of 334 men 
received non-CBCT, these are not included here.  
‡‡‡ L-field or dogleg-field. Included in this category are also 53 individuals who received RT of groin in addition to 
L-field and 2 individuals who received a reversed Y-field. 
§§§ 16 of 21 individuals received infradiafragmatic RT as first RT-field and a short while later received 
supradiafragmatic RT. 
**** RT towards bone (n=21), CNS (n=21), abdominal residual masses (n=16), intraoperative RT (n=1), skin 
lesions (n=1), non-specified sites (n=4). 
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Table 2. Cumulative incidences of metachronous contralateral TC according to 
treatment, age and histology at first TC and specified follow-up time 
 
 <5 years <10 years <15 years <20 years 
  n       %       95% CI      n       %       95% CI      n        %        95% CI        n        %          95% CI 
Total 82 1.5 1.2-1.8 157 2.8 2.4-3.3 192 3.5 3.1-4.1 209 4.0 3.5-4.6 
Age at diagnosis             
<30 y 38 1.8 1.3-2.4 86 4.1 3.3-5.0 106 5.2 4.3-6.2 118 6.0 5.0-7.1 
30 y 44 1.3 0.9-1.7 71 2.0 1.6-2.6 86 2.6 2.1-3.1 91 2.8 2.3-3.4 
Treatment, all 
patients 
            
Surgery only* 24 1.6 1.1-2.4 52 3.6 2.8-4.7 62 4.5 3.5-5.7 68 5.4 4.2-6.8 
CT 25 1.0 0.7-1.5 52 2.1 1.6-2.7 63 2.7 2.1-3.4 69 3.2 2.5-4.0 
RT 32 2.0 1.4-2.8 50 3.2 2.4-4.2 64 4.1 3.2-5.2 69 4.5 3.6-5.6 
CT + RT 1 0.5 0.1-2.5 3 1.4 0.4-3.9 3 1.4 0.4-3.9 3 1.4 0.4-3.9 
Treatment, age 
<30 y 
            
Surgery only* 11 1.8 1.0-3.1 28 4.7 3.2-6.6 36 6.3 4.5-8.5 42 8.0 5.8-10.6 
CT 18 1.6 1.0-2.5 40 3.6 2.6-4.8 46 4.2 3.1-5.6 50 4.8 3.6-6.3 
RT 9 2.5 1.2-4.6 16 4.5 2.7-7.0 22 6.3 4.0-9.1 24 6.9 4.6-10.0 
CT + RT 0 0 0 2 2.9 0.6-9.1 2 2.9 0.6-9.1 2 2.9 0.6-9.1 
Treatment, age 
30 y  
            
Surgery only* 13 1.5 0.9-2.5 24 2.9 1.9-4.2 26 3.2 2.1-4.6 26 3.2 2.1-4.6 
CT 7 0.5 0.2-1.0 12 0.9 0.5-1.5 17 1.4 0.9-2.2 19 1.7 1.1-2.7 
RT 23 1.9 1.2-2.8 34 2.8 2.0-3.9 42 3.5 2.6-4.7 45 3.8 2.8-5.0 
CT + RT 1 0.7 0.1-3.6 1 0.7 0.1-3.6 1 0.7 0.1-3.6 1 0.7 0.1-3.6 
Histology, all 
patients 
            
Seminoma 44 1.5 1.1-2.0 78 2.7 2.1-3.3 97 3.4 2.8-4.2 104 3.8 3.1-4.6 
Nonseminoma 38 1.4 1.0-1.9 79 3.0 2.4-3.7 95 3.7 3.0-4.4 105 4.3 3.5-5.1 
Histology, age 
<30 y 
            
Seminoma 13 2.1 1.2-3.4 26 4.2 2.8-5.9 35 5.8 4.1-7.9 38 6.6 4.7-8.8 
Nonseminoma 25 1.7 1.1-2.4 60 4.0 3.1-5.1 71 4.9 3.8-6.1 80 5.8 4.6-7.1 
Histology, age 
30 y 
            
Seminoma 31 1.3 0.9-1.9 52 2.3 1.7-2.9 62 2.8 2.2-3.5 66 3.1 2.4-3.9 
Nonseminoma 13 1.1 0.6-1.8 19 1.6 1.0-2.5 24 2.1 1.4-3.1 25 2.3 1.5-3.3 




                                                          
Note: n refers to cumulative number of men developing metachronous contralateral TC up until specified follow-up 
time. Age refers to age at diagnosis of first TC, dichotomized on <30 or ≥30 years.  
Abbreviations: TC, testicular cancer; n, number; 95% CI, 95% confidence interval; y, years. CT, chemotherapy; 
RT, radiotherapy; CT + RT, combination of CT and RT. 
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Table 3. SIRs for metachronous contralateral TC according to treatment, age and 
histology at first TC and follow-up time  
 No. of 
events 
SIR 95% CI 
Total 218 13.1 11.5-15.0 
Treatment, first TC    
Surgery only*  72 16.3 12.9-20.5 
CT  71  9.1  7.2-11.5 
RT  72 17.7 14.1-22.3 
CT + RT    3   8.6  2.8-26.7 
Age, dichotomized    
<30 years 125 13.4 11.2-15.9 
≥30 years   93 12.8 10.4-15.7 
Age at diagnosis    
16-20 years   9   8.5   4.4-16.4 
20-30 years 116 14.0 11.7-16.8 
30-40 years  76 13.6 10.9-17.0 
40-50 years 14 10.3   6.1-17.4 
>50 years   3   9.6   3.1-29.6 
Histology    
Seminoma 107 14.7 12.2-17.8 
Nonseminoma 111 11.9 9.9-14.3 
Follow-up time    
<5 years 82 17.0 13.7-21.2 
5-10 years 75 15.5 12.3-19.4 
10-15 years 35 10.4 7.4-14.4 
15-20 years 17 8.7 5.4-13.9 
>20 years† 9 5.6 2.9-10.7 
Abbreviations: SIRs, standardized incidence ratios; TC, testicular cancer; no, number; 95% CI, 95% 
confidence interval; CT, chemotherapy; RT, radiotherapy; CT + RT, combination of CT and RT.
* Includes men treated with surveillance and men treated with retroperitoneal lymph node dissection in addition to 
orchiectomy. 
† The longest time interval between first and second TC was 27.1 years. 
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Table 4. Age-adjusted HRs for metachronous contralateral TC according to treatment 
groups, treatment intensity, age and histology at first TC. 
 
 HR 95% CI P-value 
Treatment    
Surgery only 1 ref ref 
CT 0.55 0.40-0.76 <0.001 
RT 1.10 0.79-1.54 0.580 
CT + RT 0.50 0.16-1.57 0.233 
No. of CBCT cycles    
Surgery only 1 ref ref 
1 1.01 0.52-1.96 0.983 
2 0.74 0.40-1.36 0.332 
3 0.53 0.29-0.97 0.040 
4 0.41 0.25-0.66 <0.001 
>4 0.21 0.07-0.66 0.008 
Carboplatin, adjuvant* 1.22 0.62-2.39 0.565 
RT field    
Surgery only 1 ref ref 
L-field 1.17 0.78-1.62 0.521 
Paraaortal 0.75 0.34-1.64 0.468 
RT dose for first abdominal RT-field 
 
   
Surgery only 1 ref ref 
20-29 Gy 1.24 0.77-1.98 0.383 
30-39 Gy 1.04 0.70-1.55 0.832 
≥40 Gy 1.17 0.50-2.70 0.721 
Age at diagnosis†     
<30 years 1 ref ref 
≥30 years 0.47 0.36-0.62 <0.001 
Histology    
Age-adjusted    
Seminoma 1 ref ref 
Nonseminoma 0.73 0.55-0.98 0.034 
Multivariable‡    
Seminoma 1 ref ref 
Nonseminoma 0.97 0.65-1.45 0.883 
* Carboplatin monotherapy, carboplatin in adjuvant setting for stage 1 seminoma. 
† Not age adjusted 
‡ Adjusted for treatment in addition to age. 
 
 
                                                          
Note: Significant results marked with bold. Age refers to age at diagnosis of first TC, dichotomized 
on <30 or ≥30 years. 
 
Abbreviations: HR, hazard ratio; TC, testicular cancer; 95% CI, 95% confidence interval; ref, reference; CT, 
chemotherapy; RT, radiotherapy; CT + RT, combination of CT and RT; no, number; CBCT, cisplatin-based 



















Excluded (n=274, 4.3%) 
 Extragonadal localization (ICD-7 178.4) (n=180) 
 Localization ductus deferens or funicle (ICD-
7 178.3) (n=24) 
 Localization epididymis (ICD-7 178.2) (n=4) 
 Age < 16 years (n=66) 
   
  
Males diagnosed with germ cell TC in the NCR (coded 
with localization ICD-7 178.x) between 01/01/1980-
12/31/2009 (n=6354) 
Excluded (n=333 5.5%) 
 Previous diagnosis of non-TC cancer (n=58) 
 TC before 1980 (n=27) 
 Extragonadal localization (n=51) 
 Clinical data missing (n=55) 
 Other histology than GC cancer (n=99) 
 Treated abroad (n=11) 
 Clincial diagnosis only/histology not performed 
(n=11) 
 Other causes (n=2) 
 Synchronous non-TC diagnosis (n=19) 
 
 
Cohort for the analysis of metachronous contralateral 
TC = study population (n=5620, 88.4%) 
Dataset used as basis for information letter                
(n=6080, 95.7%) 
 Declined to participate (n=23, 0.38%) 
 
Dataset used as basis for collection of clinical data 
(n=6057, 95.3%) 
 
Excluded from the present study (n=104, 1.8%) due to the 
following events <2 months after first primary TC-
diagnosis: 
 Synchronous bilateral TC (n=61)  
 Death (n=35 (of which 7 were also diagnosed 
with synchronous bilateral TC))  
 Emigration (n=8 (of which 3 were also 
diagnosed with bilateral TC)) 
Cohort of TCS with complete clinical data              
(n=5724, 90.1%) 
Abbreviations: TC, testicular cancer; NCR, the Norwegian Cancer Registry; ICD-7, International Classification of Diseases version 7, GC, 
germ cell; TCS, testicular cancer survivors. 
 
 30 
Supplemental Table S1. Age-adjusted HRs for Metachronous Contralateral TC 
According to Cumulative Cisplatin, Platinum, and Bleomycin doses at First TC* 
 
 HR 95% CI P-value 
Cumulative cisplatin dose, mg/m2    
Surgery only 1 ref ref 
1-100 1.01 0.52-1.96 0.984 
101-200 0.74 0.40-1.36 0.331 
201-300 0.53 0.29-0.98 0.043 
301-400 0.43 0.27-0.70 0.001 
>400 0.14 0.03-0.52 0.004 
Carboplatin 1.15 0.62-2.12 0.667 
Cumulative total platinum dose, mg/m2†    
Surgery only 1 ref ref 
1-100 1.01 0.52-1.96 0.984 
101-200 0.91 0.56-1.47 0.697 
201-300 0.53 0.29-0.99 0.045 
301-400 0.46 0.29-0.72 0.001 
>400 0.12 0.03-0.50 0.003 
Cumulative bleomycin dose, IU    
Surgery only 1 ref ref 
1-100 000 0.92 0.50-1.70 0.789 
100 001-200 000 0.55 0.26-1.14 0.107 
200 001-300 000    0.46 0.30-0.69 <0.001 
>300 000 0.29 0.07-1.19 0.086 
Chemotherapy without bleomycin 0.84 0.47-1.50 0.550 
Note: Significant results marked with bold.  
 
 
Abbreviations: HR, hazard ratio; TC, testicular cancer; 95% CI, 95% confidence interval; ref, reference 
 
* When analysing the effect of cumulative doses, the proportional hazard assumption was violated for some 
treatment groups. We fitted new models with an interaction effect between follow-up time and the selected 
treatment groups and compared model fit using BIC. In all cases, the best fit was provided by the simple model 
without interaction effects, and hence the results from these are presented.   
† Cumulative total platinum doses contain cumulative doses of cisplatin and/or carboplatin. For carboplatin, the 
corresponding cisplatin-equivalent doses were estimated by dividing the carboplatin doses by four (Ozols Cancer 
Treat Rev. 1985).  
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Supplemental Table S2. Time to metachronous contralateral TC according to 
characteristics at first TC 
  
 Individuals developing 
metachronous contralateral 
TC (n=218) 
By time since treatment at first TC, years  
Surgery only* 7.0 (4.3-10.0) 
CT 5.8 (3.2-10.9) 
RT 6.5 (2.7-10.7) 
CT + RT                5.9 (4.9-6.2) 
By age at first TC, dichotomized, years  
<30 years 7.2 (4.4-10.9) 
≥30 years                5.3 (2.6-9.3) 
By histology at first TC, years  
Seminoma 6.7 (3.2-10.5) 
Nonseminoma 5.9 (4.1-10.9) 
Note: Data are presented as median (IQR). 
Abbreviations: TC, testicular cancer; n; number; CT, chemotherapy; RT, radiotherapy; CT + RT, 
combination of CT and RT; IQR, interquartile range 
 
* Includes men treated with surveillance and men treated with retroperitoneal lymph node dissection in 












Supplemental Table S3. Patient characteristics at diagnosis of metachronous 
contralateral TC 
  
 Individuals developing 
metachronous contralateral 
TC (n=218) 
Histology, second TC  
Seminoma 157  (72) 
Nonseminoma  58   (27) 
Missing    3    (1.4) 
Disease stage, second TC†   
I 184  (84) 
Mk+/II   16   (7.3) 
III    3    (1.4) 
IV    4    (1.8) 
Missing    11   (5.1) 
Treatment, second TC  
Surgery only 115  (53) 
CT†   71  (33) 
RT     16   (7.3) 
CT + RT                      0 
Missing    16   (7.3) 
Note: Data are presented as n (%). 
Abbreviations: TC, testicular cancer; n; number; Mk+, marker positive; CT, chemotherapy; RT, 
radiotherapy; CT + RT, combination of CT and RT;  
 
 
 
